Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17743
Country/Region: Nigeria
Year: 2016
Main Partner: Pro-Health International
Main Partner Program: NA
Organizational Type: Implementing Agency
Funding Agency: HHS/CDC
Total Funding: $869,142 Additional Pipeline Funding: $191,943

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $192,570
Care: Orphans and Vulnerable Children (HKID) $214,229
Care: TB/HIV (HVTB) $72,164
Care: Pediatric Care and Support (PDCS) $38,626
Laboratory Infrastructure (HLAB) $0
Testing: HIV Testing and Counseling (HVCT) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: Adult Treatment (HTXS) $334,053
Treatment: Pediatric Treatment (PDTX) $17,500
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 3,822
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 3,389
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 34,855
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 20,077
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 62,143
HTS_TST Service Delivery Point (Facility): Index testing 2017 104
HTS_TST Service Delivery Point (Facility): Inpatient 2017 104
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 51
HTS_TST Service Delivery Point (Facility): Other PITC 2017 3
HTS_TST Service Delivery Point (Facility): Outpatient 2017 29,984
HTS_TST Service Delivery Point (Facility): Pediatric 2017 7,211
HTS_TST Service Delivery Point (Facility): PMTCT 2017 12,216
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 1,232
HTS_TST Service Delivery Point (Facility): VCT 2017 11,238
HTS_TST Sum of Aggregated Age/Sex <15 2017 7,211
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 54,932
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 62,143
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 45
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 33
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 524
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 381
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 5
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 6
LAB_PT CD4: Number of laboratories that perform this testing 2017 6
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 5
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 6
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 6
OVC_SERV Age/Sex: 18+ Female 2017 270
OVC_SERV Age/Sex: 18+ Male 2017 268
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 2,446
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 2,446
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 5,430
OVC_SERV Sum of Age/Sex disaggregates 2017 538
PMTCT_ART Already on ART at beginning of current pregnancy 2017 78
PMTCT_ART New on ART 2017 79
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 12,216
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 109
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 49
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 2
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 6
PMTCT_EID Sum of Infant Age disaggregates 2017 158
PMTCT_STAT By: Known positives at entry 2017 91
PMTCT_STAT By: Number of new positives identified 2017 87
PMTCT_STAT Number of new ANC and L&D clients 2017 12,858
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 12,216
PMTCT_STAT Sum of Positives Status disaggregates 2017 178
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 7
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 129
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 6
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 119
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 289
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 261
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 165
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 149
TB_SCREENDX Screen Result: Screened Positive for TB 2017 185
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 5,442
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 2,161
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 181
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 215
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 7,999
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 40
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 860
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 28
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 593
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 1,521
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 1,691
TX_CURR Aggregated Age/Sex: <15 Female 2017 112
TX_CURR Aggregated Age/Sex: <15 Male 2017 135
TX_CURR Aggregated Age/Sex: 15+ Female 2017 4,223
TX_CURR Aggregated Age/Sex: 15+ Male 2017 1,663
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 6,133
TX_CURR Sum of Aggregated Age/Sex <15 2017 247
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 5,886
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 6,133
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 17
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 13
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 454
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 401
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 885
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 885
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 6,133
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 5,519
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 131
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 149
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 3,758
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 1,481
TX_PVLS Numerator: Indication: Routine 2017 4,416
TX_PVLS Numerator: Indication: Targeted 2017 1,103
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 146
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 164
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 4,177
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 1,646
TX_PVLS_den Denominator: Indication: Routine 2017 4,906
TX_PVLS_den Denominator: Indication: Targeted 2017 1,227
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 21
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 26
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 630
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 251
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 928
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 1,093
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 26
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 29
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 744
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 294
Cross Cutting Budget Categories and Known Amounts Total: $113,341
Gender: Gender Based Violence (GBV) $43,341
GBV Prevention
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $10,000
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Human Resources for Health $40,000
Food and Nutrition: Commodities $20,000